^
Association details:
| Biomarker: | HR negative + EGFR amplification |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | RVU120 (CDK19 inhibitor, CDK8 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic Activity of CDK8/19 Inhibitor RVU120 and MEK Inhibitors in HormoneNegative Breast Cancer: Implications for Targeted Therapy
Published date:
12/02/2023
Excerpt:
These findings highlight the synergistic potential of combining RVU120 with MEK inhibitors in hormone-negative BC, particularly in TNBC with EGFR amplification and an active RAS pathway.
Secondary therapy:
MEK inhibitor
